Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Biochemical Pharmacology

• Publication date

  1997-04-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0006-2952(96)00816-7PMID 9175713
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In Vitro Metabolism of the Vitamin D Analog, 22-Oxacalcitriol, Using Cultured Osteosarcoma, Hepatoma, and Keratinocyte Cell Lines (*)

  1996cited by this paper
• The anti-proliferative and differentiation-inducing effects of vitamin D analogs are not determined by the binding affinity for the vitamin D receptor alone.

  1996cited by this paper
• New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone.

  1995cited by this paper
• Pharmacokinetic studies of vitamin D analogues: relationship to vitamin D binding protein (DBP)

  1995cited by this paper
• Comparative effects of 1,25‐dihydroxyvitamin D3 and EB 1089 on mouse renal and intestinal 25‐hydroxyvitamin D3‐24‐hydroxylase

  1995cited by this paper
• Effect of vitamin D metabolites on calcitriol degradative enzymes in renal failure.

  1994cited by this paper
• In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity.

  1993cited by this paper
• Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions.

  1993cited by this paper
• A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.

  1993cited by this paper
• EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells.

  1993cited by this paper
• 22-oxacalcitriol suppresses 25-hydroxycholecalciferol-1 alpha-hydroxylase in rat kidney.

  1992cited by this paper
• Metabolism of 22-oxacalcitriol by a vitamin D-inducible pathway in cultured parathyroid cells.

  1992cited by this paper
• EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro.

  1992cited by this paper
• 22-oxacalcitriol suppresses 25-hydroxycholecalciferol-1α-hydroxylase in rat kidney

  1992cited by this paper
• Calcipotriol (MC 903): pharmacokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3.

  1991cited by this paper
• On the mechanisms for the selective action of vitamin D analogs.

  1991cited by this paper
• The vitamin D system: 1990.

  1990cited by this paper
• The role of the vitamin D endocrine system in health and disease.

  1989cited by this paper
• Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through the C-24 oxidation pathway

  1989cited by this paper
• Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation.

  1989cited by this paper
• Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through C-24 oxidation pathway.

  1989cited by this paper
• Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo.

  1988cited by this paper
• (23S)-1,23,25-Trihydroxyvitamin D3: its biologic activity and role in 1 alpha,25-dihydroxyvitamin D3 26,23-lactone biosynthesis.

  1984cited by this paper
• Isolation and identification of 1,25-dihydroxy-24-oxo-vitamin D3 and 1,23,25-trihydroxy-24-oxo-vitamin D3. New metabolites of vitamin D3 produced by a C-24 oxidation pathway of metabolism for 1,25-dihydroxyvitamin D3 present in intestine and kidney.

  1983cited by this paper
• A new in vivo metabolite of vitamin D3: 1,25,26-trihydroxyvitamin D3.

  1981cited by this paper
• 1,25,26-trihydroxyvitamin D3: isolation, identification, and biological activity.

  1981cited by this paper
• Studies in Stereochemistry. X. The Rule of “Steric Control of Asymmetric Induction” in the Syntheses of Acyclic Systems

  1952cited by this paper

• EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells

  2024cites this paper
• GC–MS Based Metabolomics Strategy for Cost-Effective Valorization of Agricultural Waste: Groundnut Shell Extracts and Their Biological Inhibitory Potential

  2022cites this paper
• Vitamin D and its analogs

  2020cites this paper
• Specificity of the Redox Complex between Cytochrome P450 24A1 and Adrenodoxin Relies on Carbon-25 Hydroxylation of Vitamin-D Substrate

  2019cites this paper
• Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes

  2018cites this paper
• Vitamin D Signaling Modulators in Cancer Therapy.

  2016cites this paper
• The kinetic characterisation of vitamin D metabolism by human CYP24A1

  2015cites this paper
• The future of vitamin D analogs

  2014cites this paper
• The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.

  2014cites this paper
• Vitamin D receptor agonist EB1089 is a potent regulator of prostatic “intracrine” metabolism

  2014cites this paper
• 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D.

  2012cites this paper
• Vitamin D Analogs and Their Clinical Uses

  2012cites this paper
• Vitamin D analogs.

  2012cites this paper
• Vitamin D and Prostate Cancer

  2011cites this paper
• Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D‐binding protein and resistance to metabolism

  2011cites this paper
• A new insight into the role of rat cytochrome P450 24A1 in metabolism of selective analogs of 1α,25-dihydroxyvitamin D₃.

  2011cites this paper
• Metabolism and Catabolism of Vitamin D, Its Metabolites, and Clinically Relevant Analogs

  2010cites this paper
• Calcitriol and Vitamin D Analogs

  2010cites this paper
• EB1089 inhibits the parathyroid hormone–related protein–enhanced bone metastasis and xenograft growth of human prostate cancer cells

  2009cites this paper
• Vitamin D and Analogues

  2008cites this paper
• Antioxidants and doxorubicin supplementation to modulate CD14 expression and oxidative stress induced by vitamin D3 and seocalcitol in HL60 cells.

  2007cites this paper
• Mechanism and potential of the growth-inhibitory actions of vitamin D and ana-logs.

  2007cites this paper
• Vitamin D Analogs and Their Role in Prostate Cancer

  2006cites this paper
• Novel cytotoxic and biological agents for prostate cancer: where will the money be in 2005?

  2005cites this paper
• CHAPTER 81 – Analog Metabolism

  2005cites this paper
• CHAPTER 82 – Mechanisms for the Selective Actions of Vitamin D Analogs

  2005cites this paper
• Calcitriol in cancer treatment: from the lab to the clinic.

  2004cites this paper
• Profiling 1,25-dihydroxyvitamin D3-regulated gene expression by microarray analysis.

  2004cites this paper
• Vitamin D-related Therapies in Prostate Cancer

  2004cites this paper
• Significant experimental decrease of the hepatocellular carcinoma incidence in C3H/Sy mice after long-term administration of EB1089, a vitamin D analogue.

  2003cites this paper
• p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells.

  2003cites this paper
• Prostate cancer cell type-specific regulation of the human PTHrP gene via a negative VDRE.

  2003cites this paper
• A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

  2002cites this paper
• ReviewVitamin D and Prostate Cancer

  2002cites this paper
• Vitamin D Receptor As an Intestinal Bile Acid Sensor

  2002cites this paper
• Vitamin D and Analogs

  2002cites this paper
• Vitamin D and prostate cancer.

  2002cites this paper
• Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues.

  2001cites this paper
• Sensitive analysis of 1alpha,25-dihydroxyvitamin D3 in biological fluids by liquid chromatography-tandem mass spectrometry.

  2001cites this paper
• Examination of structurally selective derivatization of vitamin D(3) analogues by electrospray mass spectrometry.

  2001cites this paper
• Polyclonal antibodies to EB1089 (seocalcitol), an analog of 1alpha,25-dihydroxyvitamin D(3)*.

  2001cites this paper
• Polyclonal antibodies to EB1089 (seocalcitol), an analog of 1α,25-dihydroxyvitamin D3☆

  2001cites this paper
• Vitamin D analogs.

  2001cites this paper
• Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis.

  2001cites this paper
• Sensitive analysis of 1α,25-dihydroxyvitamin D3 in biological fluids by liquid chromatography–tandem mass spectrometry

  2001cites this paper
• Contribution of several metabolites of the vitamin D analog 20-epi-22-oxa-24a,26a,27a-tri-homo-1,25-(OH)(2) vitamin D(3) (KH 1060) to the overall biological activity of KH1060 by a shared mechanism of action.

  2000cites this paper
• Pharmacokinetics and metabolism of a vitamin D analogue (Seocalcitol) in rat and minipig

  2000cites this paper
• The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells.

  2000cites this paper
• Mechanisms for the selective actions of vitamin D analogues.

  2000cites this paper
• Agonist-triggered modulation of the activated and silent state of the vitamin D(3) receptor by interaction with co-repressors and co-activators.

  2000cites this paper
• The impact of functional vitamin D(3) receptor conformations on DNA-dependent vitamin D(3) signaling.

  2000influential citation
• Determination of the vitamin D analog EB 1089 (seocalcitol) in human and pig serum using liquid chromatography-tandem mass spectrometry.

  2000cites this paper
• Vitamin D and Prostate Cancer

  1999cites this paper
• Metabolism of the vitamin D3 analogue EB1089 alters receptor complex formation and reduces promoter selectivity

  1998influential citation
• Current understanding of the molecular actions of vitamin D.

  1998cites this paper
• New 1 alpha,25-dihydroxy vitamin D3 analogues with side chains attached to C-18: synthesis and biological activity.

  1998cites this paper
• New 1α,25-dihydroxy vitamin D3 analogues with side chains attached to C-18: synthesis and biological activity

  1998cites this paper
• EB 1089, a novel vitamin D analog with strong antiproliferative and differentiation-inducing effects on target cells.

  1997cites this paper
• Metabolism of the vitamin D analog EB1089 by cultured human cells: redirection of hydroxylation site to distal carbons of the side-chain.

  1997cites this paper
• Development of new vitamin D analogs

  1997cites this paper
• The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity.

  1997cites this paper